http://www.sciencedirect.com/science/article/pii/S1525001617305075
Abstract
The
failure of therapeutic agents to cross the blood-brain barrier (BBB)
has been a major impediment in the treatment of neurological disorders
and brain tumors. We have addressed this issue using an immunoliposome
nanocomplex (designated scL) that delivers therapeutic nucleic acids
across the BBB into the deep brain via transcytosis mediated by
transferrin receptors. We validated brain delivery of payloads after
systemic administration by monitoring uptake of fluorescently labeled
payloads and by confirming up- or down-modulation of specific target
gene expression in the brain, mainly in neuronal cells. As proof of
concept for the therapeutic potential of our delivery system, we
employed scL delivering an siRNA targeting tumor necrosis factor alpha
to suppress neuroinflammation and neuronal apoptosis and to protect mice
in lethal endotoxemia triggered by bacterial lipopolysaccharide. Brain
delivery of therapeutic payloads via scL has major implications for the development of treatments for neurological disorders and brain tumors.
Choose an option to locate/access this article:
Check if you have access through your login credentials or your institution
Check Access
No comments:
Post a Comment